BALAXI Stock Overview
Engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Balaxi Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹74.73 |
| 52 Week High | ₹151.45 |
| 52 Week Low | ₹73.35 |
| Beta | 0.79 |
| 1 Month Change | -5.33% |
| 3 Month Change | -32.57% |
| 1 Year Change | -15.54% |
| 3 Year Change | -24.55% |
| 5 Year Change | 370.59% |
| Change since IPO | 2,637.36% |
Recent News & Updates
Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues
Nov 13
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Recent updates
Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues
Nov 13These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost
Feb 10Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested
May 20A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Feb 03Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Sep 06Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively
Jun 03Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 12Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 27
Shareholder Returns
| BALAXI | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -10.1% | -0.2% | -2.1% |
| 1Y | -15.5% | 44.5% | 22.5% |
Return vs Industry: BALAXI underperformed the Indian Healthcare industry which returned 44.5% over the past year.
Return vs Market: BALAXI underperformed the Indian Market which returned 22.5% over the past year.
Price Volatility
| BALAXI volatility | |
|---|---|
| BALAXI Average Weekly Movement | 4.8% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: BALAXI has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: BALAXI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1942 | 600 | Ashish Maheshwari | balaxipharma.in |
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India and internationally. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes.
Balaxi Pharmaceuticals Limited Fundamentals Summary
| BALAXI fundamental statistics | |
|---|---|
| Market cap | ₹3.80b |
| Earnings (TTM) | ₹355.97m |
| Revenue (TTM) | ₹2.64b |
10.7x
P/E Ratio1.4x
P/S RatioIs BALAXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BALAXI income statement (TTM) | |
|---|---|
| Revenue | ₹2.64b |
| Cost of Revenue | ₹1.42b |
| Gross Profit | ₹1.22b |
| Other Expenses | ₹862.64m |
| Earnings | ₹355.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.99 |
| Gross Margin | 46.23% |
| Net Profit Margin | 13.50% |
| Debt/Equity Ratio | 14.1% |
How did BALAXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 02:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Balaxi Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|